DOCSLIB.ORG

Manufacturers and Wholesalers Street City ST Zip Submitted Under

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Manufacturers and Wholesalers Street City ST Zip Submitted Under 2019 AB128 Code of Conduct Compliant Companies Report Submitted under Company Name: Companies, Affilated Companies or Manufacturers and Wholesalers Street City ST Zip Subsidiaries included on compliance form Abbott Cardiac Arrhythmia and Heart Failure Abbott Laboratories Abbott Diabetes Care Division Abbott Laboratories Abbott Diagnostic Division Abbott Laboratories 100 Abbott Park Road, Dept. EC10, Bldg. Abbott Laboratories APGA-2 Abbott Park IL 60064 Abbott Laboratories Abbott Molecular Division Abbott Laboratories Abbott Neuromodulation Abbott Laboratories Abbott Nueromodulation Abbott Laboratories Abbott Nutrition Products Division Abbott Laboratories Abbott Rapid Diagnostics Abbott Laboratories Abbott Structural Heart Abbott Laboratories Abbott Vascular Division Abbott Laboratories AbbVie, Inc. 1 N. Waukegan Road North Chicago IL 60064 AbbVie, Inc. Acadia Phamaceuticals 3611 Valley Centre Drive, Suite 300 San Diego CA 92130 Acadia Phamaceuticals Acclarent, Inc. 1525-B O'Brien Dr. Menlo Park CA 94025 Acclarent, Inc. Accuri Cyometers, Inc. Becton Dickinson and Company Ace Surgical Supply, Inc. 1034 Pearl St. Brockton MA 02301 Ace Surgical Supply, Inc. Acell, Inc. 6640 Eli Whitney Drive, Suite 200 Columbia MD 21046 Acell, Inc. Acera Surgical, Inc 10880 Baur Blvd St Louis MO 63132 Acera Surgical, Inc Achaogen, Inc 1 Tower Place Suite 400 South San Francisco CA 94080 Achaogen, Inc Aclaris Therapeutics, Inc. 640 Lee Road, Suite 200 Wayne PA 19087 Aclaris Therapeutics, Inc. Acorda Therapeutics, Inc. 420 Sawmill River Road Ardsley NY 10532 Acorda Therapeutics, Inc. AcriVet Inc. Valeant Pharmaceuticals Adamas Pharma, LLC Adamas Pharmaceuticals, Inc. Adamas Pharmaceuticals, Inc. 1900 Powell St., Suite 750 Emeryville CA 94608 Adamas Pharmaceuticals, Inc. Advanced Respiratory, Inc. Hill-Rom Holdings, Inc. Advanced Sterilization Products Services, Inc. Ethicon Inc. Aerie Pharmaceuticals, Inc. 2030 Main St., Suite 1400 Irvine CA 92614 Aerie Pharmaceuticals, Inc. Aesculap Implant Systems, Inc. Aesculap, Inc. Aesculap, Inc. 3773 Corporate Parkway Center Valley PA 18034 Aesculap, Inc. Aesthera Corporation Valeant Pharmaceuticals Afaxys, Inc. PO Box 20158 Charleston SC 29413 Afaxys, Inc. Agilent Technologies Orange County CA Agilent Technologies Agios Pharmaceuticals, Inc. 88 Sydney St Cambridge MA 2139 Agios Pharmaceuticals, Inc. AGMS Inc. Valeant Pharmaceuticals Akebia Therapeutics 245 First Street, Floor 12 Cambridge MA 2142 Akebia Therapeutics Alamo Pharma Services, Inc. Mission Pharmacal Company Alcon Laboratories, Inc. 6201 South Freeway Fort Worth TX 76134 Alcon Laboratories, Inc. 1 of 17 Published 8/16/2019 Alden Optical Laboratories, Inc. Valeant Pharmaceuticals Aldenex Vision LLC Valeant Pharmaceuticals Alexion Pharmaceuticals, Inc 121 Seaport Boulevard Boston MA 2210 Alexion Pharmaceuticals, Inc ALK-Abello, Inc 1700 Royston Lane Round Rock TX 78664 ALK-Abello, Inc Alkermes, Inc. 852 Winter Street Waltham MA 02451 Alkermes, Inc. Allen Medical Systems, Inc. 825 Winter Waltham MA 02461 Hill-Rom Holdings, Inc. Allergan, PLC 5 Giralda Farms Madison NJ 07940 Allergan, PLC Almirall, LLC 707 Eagleview Blvd Ste 200 Exton PA 19341 Almirall, LLC Alverix, Inc. Becton Dickinson and Company AMAG Pharma USA 1099 Winter Street, Suite 3000 Waltham MA 02450 AMAG Pharmaceuticals, Inc. AMAG Pharmaceuticals, Inc. 1100 Winter Street Waltham MA 02451 AMAG Pharmaceuticals, Inc. Amarin Corp. PLC Bedminster NJ 07922 Amarin Pharma, Inc. Amarin Pharma, Inc. 1430 Route 206 Suite 200 Bedminster NJ 07921 Amarin Pharma, Inc. Amarin Pharmaceuticals Inc. Valeant Pharmaceuticals Amarin Pharmaceuticals Ireland Ltd. 1430 Route 206 Bedminster NJ 07923 Amarin Pharma, Inc. AMATECH Corporation Hill-Rom Holdings, Inc. Amerisource Health Services Corp (dba American Health Packaging) 2550 John Glenn Ave, Suite A Columbus OH 43217 AmerisourceBergen Corporation AmerisourceBergan Drug Corporation AmerisourceBergen Corporation AmerisourceBergen Corporation 1300 Morris Drive Chesterbrook PA 19087 AmerisourceBergen Corporation AmerisourceBergen Drug Corporation AmerisourceBergen Corporation AMF Support Surfaces, Inc. Hill-Rom Holdings, Inc. Amgen, Inc. 1 Amgen Center Drive Thousand Oaks CA 91320 Amgen, Inc. Amgen, USA Amgen, Inc. Amneal Pharmaceuticals 400 Crossing Blvd Bridgewater NJ 8807 Amneal Pharmaceuticals Amphastar Pharmaceuticals, Inc. 11570 Sixth St. Rancho Cucamnga CA 91730 Amphastar Pharmaceuticals, Inc. AMS Sales, LLC Boston Scientific Corporation Animas Corporation LifeScan, Inc. Anodyne Medical Devices, Inc. Hill-Rom Holdings, Inc. 1120 S Capital of TX Hwy, Bldg 1, ste Apollo Endosurgery, Inc. 300 Austin TX 78746 Apollo Endosurgery, Inc. ApoPharma USA Inc. 2400 N. Commerce Parkway Weston FL 33326 ApoPharma USA Inc. Applied Medical Distribution Corporation 22872 Avenida Empress Rancho Santa Margarita CA 92688 Applied Medical Resources Corporation Applied Medical Resources Corporation 22872 Avenida Empress Rancho Santa Margarita CA 92688 Applied Medical Resources Corporation Apria Healthcare, Inc 26220 Enterprise Court Lake Forest CA 92630 Apria Healthcare, Inc Aribex, Inc. 1717 West Collins Avenue Orange CA 92867 Aribex, Inc. Arkray America, Inc 5182 W. 76th St Minneapolis MN 55439 Arkray America, Inc Arkray Factory USA, Inc Arkray America, Inc Arkray USA, Inc Arkray America, Inc Armstrong Pharmaceuticals, Inc. Amphastar Pharmaceuticals, Inc. Array-BioPharma, Inc 3200 Walnut Street Boulder CO 80301 Array-BioPharma, Inc Arrow International, Inc Teleflex Incorporated Arrow Interventional, Inc Teleflex Incorporated Arthrex, Inc. 1370 Creekside Blvd Naples FL 34108 Arthrex, Inc. Ascensia Deiabetes Care US, Inc 5 Wood Hollow Rd Parsippany NJ 7054 Ascensia Deiabetes Care US, Inc 2 of 17 Published 8/16/2019 Ascension Orthopedics, Inc. Integra LifeSciences Corporation ASD Specialty Healthcare, Inc.(dba Oncology Supply and Besse Medical) AmerisourceBergen Corporation Aspen Surgical Products Holdings, Inc. Hill-Rom Holdings, Inc. Aspen Surgical Products, Inc. Hill-Rom Holdings, Inc. Assertio Therapeutics 100 S. Saunders Dr Ste 300 Lake Forest IL 60045 Assertio Therapeutics Astellas Pharma US, Inc. One Astellas Way Northbrook IL 60062 Astellas Pharma US, Inc. Asthmatx, Inc. Boston Scientific Corporation AstraZenca LP 1800 Concord Pike Wilmington DE 19850 AstraZenca Pharmaceuticals LP AstraZenca Pharmaceuticals LP 1800 Concord Pike Wilmington DE 19850 AstraZenca Pharmaceuticals LP Astute Medical, Inc. 3550 General Atomics Court, Bldg. 2 San Diego CA 92121 Astute Medical, Inc. Aton Pharma, Inc. Valeant Pharmaceuticals Atos Medical, Inc. 11390 W Theodore Trecker Way West Allis WI 53214 Atos Medical, Inc. AtriCure Europe B.V., Inc. AtriCure, Inc. AtriCure Germany GmbH. AtriCure, Inc. AtriCure Hong Kong Limited , Inc. AtriCure, Inc. AtriCure LLC AtriCure, Inc. AtriCure Spain S.L. AtriCure, Inc. AtriCure, Inc. 7555 Innovation Way Mason OH 45040 AtriCure, Inc. Audrey Enterprise, LLC Valeant Pharmaceuticals Augmenix 201 Burlington Road Bedford MA 01870 Augmenix Avanir Pharmaceuticals 30 Enterprise, Suite 400 Aliso Viejo CA 92656 Avanir Pharmaceuticals Avid Radiopharmaceuticals, Inc. Eli Lilly and Company AVITA Medical Americas, LLC 28159 Avenue Stanford Ste 220 Valencia CA 91355 AVITA Medical Americas, LLC Avrio Health L.P. (formerly Purdue Products LP) One Stamford Forum / 201 Tresser Blvd. Stamford CT 06901 Purdue Pharma LP AYTU Bioscience 373 Inverness Parkway, Suite 206 Englewood CO 80112 AYTU Bioscience Azeo Processing, Inc. Valeant Pharmaceuticals B&B Pharmaceuticals, Inc. 8591 Prairie Train Drive Ste C-60- Englewood CO 80112 B&B Pharmaceuticals, Inc. B&L Financial Holdings Corp. Valeant Pharmaceuticals B. Braun Interventional Systems, Inc. 824 Twelfth Avenue Bethlehem PA 18018 B. Braun Interventional Systems, Inc. B. Braun Medical, Inc. 824 Twelfth Avenue Bethlehem PA 18018 B. Braun Medical, Inc. B+L Diagnostics, Inc. Valeant Pharmaceuticals Bard Access Systems, Inc. C.R. Bard, Inc. Bard Medical Division C.R. Bard, Inc. Bard Peripheral Vascular, Inc. C.R. Bard, Inc. Bausch & Lomb China, Inc. Valeant Pharmaceuticals Bausch & Lomb Holdings Incorporated Valeant Pharmaceuticals Bausch & Lomb Incorporated Valeant Pharmaceuticals Bausch & Lomb International Inc. Valeant Pharmaceuticals Bausch & Lomb Luxembourg S.à.r.l. ‐ US Branch Valeant Pharmaceuticals Bausch & Lomb Pharma Holdings Corp. Valeant Pharmaceuticals Bausch & Lomb Realty Corporation Valeant Pharmaceuticals Bausch & Lomb South Asia, Inc. Valeant Pharmaceuticals Bausch & Lomb Technology Corporation Valeant Pharmaceuticals 3 of 17 Published 8/16/2019 Bausch Foundation Valeant Pharmaceuticals Baxter Healthcare Corporation One Baxter Parkway Deerfield IL 60015 Baxter Healthcare Corporation Bayer Consumer Heath Division Bayer US, LLC Bayer Crop Science, Animal Health Business Bayer US, LLC Bayer Healthcare Pharmaceuticals, Inc. Bayer US, LLC Bayer US, LLC 100 Bayer Boulevard Whippany NJ 07981 Bayer US, LLC BD Biosciences Sys & Reagents, Inc. Becton Dickinson and Company BD Infusion Therapy Systems, Inc. Becton Dickinson and Company Beckman Coulter, Inc. 250 S. Kraemer Boulevard Brea CA 92821 Beckman Coulter, Inc. Becton Dickinson and Company and subsidiaries 1 Becton Drive Franklin Lakes NJ 07417 Becton Dickinson and Company Biocomp Pharma, Inc. Mission Pharmacal Company Biocompatibles, Inc. 300 Barr Harbor Drive, Suite 810 West Conshohocken PA 19428 BTG International Inc. BioHorizons Implant Systems, Inc. 2300 Riverchase Center Birmingham AL 35242 BioHorizons Implant Systems, Inc. BioMarin Pharmaceutical, Inc. 105
Load more

Recommended publications
  • Transcept Pharmaceuticals, Inc
    Table of Contents SCHEDULE 14A (RULE 14A 101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by x Definitive Proxy Statement Rule 14a-6(e)(2)) ¨ Definitive Additional Materials ¨ Soliciting Material Pursuant to §240.14a-12 Transcept Pharmaceuticals, Inc. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required. ¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: ¨ Fee paid previously with preliminary materials. ¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: Table of Contents NOTICE OF ANNUAL MEETING OF STOCKHOLDERS JUNE 23, 2011 To Our Stockholders: NOTICE IS HEREBY GIVEN that the Annual Meeting of Stockholders of Transcept Pharmaceuticals, Inc., a Delaware corporation, will be held on Thursday, June 23, 2011, at 8:30 a.m., local time, at our office located at 1003 West Cutting Blvd., Suite 110, Point Richmond, California 94804, for the following purposes: 1.
    [Show full text]
  • Infectious Diseases
    2013 MEDICINES IN DEVELOPMENT REPORT Infectious Diseases A Report on Diseases Caused by Bacteria, Viruses, Fungi and Parasites PRESENTED BY AMERICA’S BIOPHARMACEUTICAL RESEARCH COMPANIES Biopharmaceutical Research Evolves Against Infectious Diseases with Nearly 400 Medicines and Vaccines in Testing Throughout history, infectious diseases hepatitis C that inhibits the enzyme have taken a devastating toll on the lives essential for viral replication. and well-being of people around the • An anti-malarial drug that has shown Medicines in Development world. Caused when pathogens such activity against Plasmodium falci- For Infectious Diseases as bacteria or viruses enter a body and parum malaria which is resistant to multiply, infectious diseases were the current treatments. Application leading cause of death in the United Submitted States until the 1920s. Today, vaccines • A potential new antibiotic to treat methicillin-resistant Staphylococcus Phase III and infectious disease treatments have proven to be effective treatments in aureus (MRSA). Phase II many cases, but infectious diseases still • A novel treatment that works by Phase I pose a very serious threat to patients. blocking the ability of the smallpox Recently, some infectious pathogens, virus to spread to other cells, thus 226 such as pseudomonas bacteria, have preventing it from causing disease. become resistant to available treatments. Infectious diseases may never be fully Diseases once considered conquered, eradicated. However, new knowledge, such as tuberculosis, have reemerged new technologies, and the continuing as a growing health threat. commitment of America’s biopharma- America’s biopharmaceutical research ceutical research companies can help companies are developing 394 medicines meet the continuing—and ever-changing and vaccines to combat the many threats —threat from infectious diseases.
    [Show full text]
  • Faculty Disclosure
    Faculty Disclosure In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. If an individual refuses to disclose relevant financial relationships, they will be disqualified from being a part of the planning and implementation of this CME activity. Owners and/or employees of a commercial interest with business lines or products relating to the content of the CME activity will not be permitted to participate in the planning or execution of any accredited activity. Nature of Relevant Financial Relationship Last Name Commercial Interest What Was Received For What Role AbbVie, Allergan/ Tobira Therapeutics Inc, Gilead Research Grant Research Balart Sciences Inc, Pfizer, Salix Pharmaceuticals AbbVie, Merck Honorarium Advisory Board Bau None N/A N/A Benz None N/A N/A AbbVie, Arbutus Biopharma, Dieterich Gilead Sciences, Inc., Bristol- Research Grant Consultant Myers Squibb, Merck Bayer HealthCare Pharmaceuticals, Gilead Sciences Honorarium Speaking, Consultant Inc. Bristol-Myers Squibb, Gilead Speaking, Advisory Sciences, Inc, Salix Honorarium Frenette Board Pharmaceuticals, Inc, Merck Intercept Pharmaceuticals Honorarium Advisor Conatus Pharmaceuticals Inc Honorarium Consulting Principle Investigator, Research Grant, Han Gilead Sciences,
    [Show full text]
  • Manufacturers and Wholesalers Street
    Nevada AB128 Code of Conduct Compliant Companies Manufacturers and Wholesalers Street City ST Zip 10 Edison Street LLC 13 Edison Street LLC Abbott Diabetes Care Division Abbott Diagnostic Division Abbott Electrophysiology (including Kalila Medical 2- 2016)) Abbott Laboratories 100 Abbott Park Road, Dept. EC10, Bldg. APGA-2 Abbott Park IL 60064 Abbott Medical Optics Abbott Molecular Division Abbott Nutrition Products Division Abbott Vascular Division (includes Tendyne 9-2015) AbbVie, Inc. 1 N. Waukegan Road North Chicago IL 60064 Acadia Phamaceuticals 3611 Valley Centre Drive, Suite 300 San Diego CA 92130 Accelero Health Partners, LLC Acclarent, Inc. 1525-B O'Brien Dr. Menlo Park CA 94025 Accuri Cyometers, Inc. Ace Surgical Supply, Inc. 1034 Pearl St. Brockton MA 02301 Acorda Therapeutics, Inc. 420 Sawmill River Road Ardsley NY 10532 AcriVet, Inc. Actavis W.C. Holding, Inc. Morris Corporate Center III, 400 Interpace Parkway Parsippany NJ 07054 Actavis , Inc. Actelion Pharmaceuticals US, Inc. 5000 Shoreline Court, Suite 200 S. San Francisco CA 94080 Activis 400 Interpace parkway Parsippany NJ 07054 A-Dec, Inc. 2601 Crestview Dr. Newberg OR 97132 Advanced Respiratory, Inc. Advanced Sterilization Products 33 Technology Drive Irvine CA 92618 Advanced Vision Research, Inc., dba Akorn Consumer Health Aegerion Pharmaceuticals, Inc. 101 Main Street, Suite 1850 Cambridge MA 02142 Aesculap Implant Systems, Inc. Aesculap, Inc. 3773 Corporate Parkway Center Valley PA 18034 Aesthera Corporation Afaxys, Inc. PO Box 20158 Charleston SC 29413 AGMS, Inc. Akorn (New Jersey) Inc. Page 1 of 23 Pages 2/15/2017 Nevada AB128 Code of Conduct Compliant Companies Akorn AG (formerly Excelvision AG) Akorn Animal Health, Inc.
    [Show full text]
  • United States Court of Appeals for The
    Case 14-4353, Document 100-1, 05/16/2016, 1772362, Page1 of 37 14‐4353‐cv Apotex Inc., et al., v. Acorda Therapeutics, Inc. UNITED STATES COURT OF APPEALS FOR THE SECOND CIRCUIT August Term, 2015 (Argued: November 12, 2015 Decided: May 16, 2016) Docket No. 14‐4353‐cv ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐x APOTEX INC., et al., Plaintiffs‐Appellants, ‐ v.‐ ACORDA THERAPEUTICS, INC., Defendant‐Appellee. ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐x Before: JACOBS, LIVINGSTON and DRONEY, Circuit Judges. This appeal concerns two distinct questions: the circumstances under which the filing of a citizen petition with the Food and Drug Administration provides grounds for an antitrust claim, and the scope of false advertising Case 14-4353, Document 100-1, 05/16/2016, 1772362, Page2 of 37 liability under the Lanham Act. Plaintiffs Apotex Incorporated and Apotex Corporation appeal from the judgment of the United States District Court for the Southern District of New York (Swain, J.) that granted defendant Acorda Therapeutics, Inc.’s motion to dismiss plaintiffs’ Sherman Act claim and that granted summary judgment in favor of defendant on the Lanham Act claims (Torres, J.). Because each of these conclusions was sound, we affirm. KEITH D. PARR (with Joseph N. Froehlich, Scott B. Feder, Hugh S. Balsam, James T. Peterka, and Andy J. Miller on the brief), Locke Lord LLP, Chicago, Illinois, for Appellants Apotex Incorporated & Apotex Corporation. JOHN W. NIELDS, JR. (with Jason C. Raofield and Colin P. Watson on the brief), Covington & Burling LLP, Washington, D.C. for Appellee Acorda Therapeutics, Inc. DENNIS JACOBS, Circuit Judge: The parties are rival manufacturers of tizanidine, a drug for treating spasticity.
    [Show full text]
  • NASDAQ Stock Market
    Nasdaq Stock Market Friday, December 28, 2018 Name Symbol Close 1st Constitution Bancorp FCCY 19.75 1st Source SRCE 40.25 2U TWOU 48.31 21st Century Fox Cl A FOXA 47.97 21st Century Fox Cl B FOX 47.62 21Vianet Group ADR VNET 8.63 51job ADR JOBS 61.7 111 ADR YI 6.05 360 Finance ADR QFIN 15.74 1347 Property Insurance Holdings PIH 4.05 1-800-FLOWERS.COM Cl A FLWS 11.92 AAON AAON 34.85 Abiomed ABMD 318.17 Acacia Communications ACIA 37.69 Acacia Research - Acacia ACTG 3 Technologies Acadia Healthcare ACHC 25.56 ACADIA Pharmaceuticals ACAD 15.65 Acceleron Pharma XLRN 44.13 Access National ANCX 21.31 Accuray ARAY 3.45 AcelRx Pharmaceuticals ACRX 2.34 Aceto ACET 0.82 Achaogen AKAO 1.31 Achillion Pharmaceuticals ACHN 1.48 AC Immune ACIU 9.78 ACI Worldwide ACIW 27.25 Aclaris Therapeutics ACRS 7.31 ACM Research Cl A ACMR 10.47 Acorda Therapeutics ACOR 14.98 Activision Blizzard ATVI 46.8 Adamas Pharmaceuticals ADMS 8.45 Adaptimmune Therapeutics ADR ADAP 5.15 Addus HomeCare ADUS 67.27 ADDvantage Technologies Group AEY 1.43 Adobe ADBE 223.13 Adtran ADTN 10.82 Aduro Biotech ADRO 2.65 Advanced Emissions Solutions ADES 10.07 Advanced Energy Industries AEIS 42.71 Advanced Micro Devices AMD 17.82 Advaxis ADXS 0.19 Adverum Biotechnologies ADVM 3.2 Aegion AEGN 16.24 Aeglea BioTherapeutics AGLE 7.67 Aemetis AMTX 0.57 Aerie Pharmaceuticals AERI 35.52 AeroVironment AVAV 67.57 Aevi Genomic Medicine GNMX 0.67 Affimed AFMD 3.11 Agile Therapeutics AGRX 0.61 Agilysys AGYS 14.59 Agios Pharmaceuticals AGIO 45.3 AGNC Investment AGNC 17.73 AgroFresh Solutions AGFS 3.85
    [Show full text]
  • Market Cap Close ADV
    Market Cap Close ADV 1598 67th Pctl $745,214,477.91 $23.96 225,966.94 801 33rd Pctl $199,581,478.89 $10.09 53,054.83 2399 Listing_ Revised Ticker_Symbol Security_Name Exchange Effective_Date Mkt Cap Close ADV Stratum Stratum AAC AAC Holdings, Inc. N 20160906 M M M M-M-M M-M-M Altisource Asset Management AAMC Corp A 20160906 L M L L-M-L L-M-L AAN Aarons Inc N 20160906 H H H H-H-H H-H-H AAV Advantage Oil & Gas Ltd N 20160906 H L M H-L-M H-M-M AB Alliance Bernstein Holding L P N 20160906 H M M H-M-M H-M-M ABG Asbury Automotive Group Inc N 20160906 H H H H-H-H H-H-H ABM ABM Industries Inc. N 20160906 H H H H-H-H H-H-H AC Associated Capital Group, Inc. N 20160906 H H L H-H-L H-H-L ACCO ACCO Brand Corp. N 20160906 H L H H-L-H H-L-H ACU Acme United A 20160906 L M L L-M-L L-M-L ACY AeroCentury Corp A 20160906 L L L L-L-L L-L-L ADK Adcare Health System A 20160906 L L L L-L-L L-L-L ADPT Adeptus Health Inc. N 20160906 M H H M-H-H M-H-H AE Adams Res Energy Inc A 20160906 L H L L-H-L L-H-L American Equity Inv Life Hldg AEL Co N 20160906 H M H H-M-H H-M-H AF Astoria Financial Corporation N 20160906 H M H H-M-H H-M-H AGM Fed Agricul Mtg Clc Non Voting N 20160906 M H M M-H-M M-H-M AGM A Fed Agricultural Mtg Cla Voting N 20160906 L H L L-H-L L-H-L AGRO Adecoagro S A N 20160906 H L H H-L-H H-L-H AGX Argan Inc N 20160906 M H M M-H-M M-H-M AHC A H Belo Corp N 20160906 L L L L-L-L L-L-L ASPEN Insurance Holding AHL Limited N 20160906 H H H H-H-H H-H-H AHS AMN Healthcare Services Inc.
    [Show full text]
  • Ipo Analysis
    IPO ANALYSIS Snap Research on potential upcoming IPOs from Hamilton Lane Bitcoin Investment Trust selected candidate companies. Visterra Braeburn Pharmaceuticals December, 2016 VentureDeal Snap Files S-1 Registration For $3 Billion IPO Quick Take Camera company Snap Inc. (Pending:SNAP) has filed its initial S-1 registration for a $3 billion IPO at an undisclosed valuation. Snap views the camera as the primary use of the mobile device and seeks to monetize its user base primarily through advertising. The company has a short history of rapidly growing revenues, which exceeded $400 million in 2016. Company Venice-based Snap was founded in 2012 by current CEO Evan Spiegel and current CTO Robert Murphy to initially provide users with a smartphone app that enabled them to post pictures that were automatically deleted after a brief time period. The company has since expanded its scope to include chat, video, media that does not become automatically deleted, and a camera integrated into sunglasses. Below is a brief company video on its recently introduced Spectacles product: (Source: Snap YouTube) Snap has raised in excess of $2.6 billion in several private financing rounds from numerous investors including top tier venture capital firms, corporate investors, private equity firms and government-owned investment enterprises. The company claims that 158 million people use its flagship Snapchat each day, creating over 2.5 billion 'Snaps'. Market and Competition Snap operates a largely advertising-driven business model, although it does sell its Spectacles product for $129 each. It seeks to provide advertisers with access to its user base, which has typically centered around a younger demographic, between the ages of 14-30.
    [Show full text]
  • HEALTH BENEFITS Providing Value for Our Employees
    HEALTH BENEFITS Providing Value for Our Employees March 2017 Business Roundtable CEO members lead companies with more than $6 trillion in annual revenues and nearly 15 million employees. The combined market capitalization of Business Roundtable member companies is the equivalent of nearly one-quarter of total U.S. stock market capitalization, and Business Roundtable members invest $103 billion annually in research and development — equal to 30 percent of U.S. private R&D spending. Our companies pay $226 billion in dividends to shareholders and generate $412 billion in revenues for small and medium-sized businesses annually. Business Roundtable companies also make more than $7 billion a year in charitable contributions. Please visit us at www.brt.org, check us out on Facebook and LinkedIn, and follow us on Twitter. Copyright © 2017 by Business Roundtable HEALTH BENEFITS Providing Value for Our Employees March 2017 March 2017 DEAR BUSINESS LEADERS AND STAKEHOLDERS: I am pleased to share with you a new report highlighting what leading U.S. companies are doing to improve health outcomes for our employees and their families. America’s employer-sponsored health benefits system is the foundation of health care in the United States. Of the 209 million Americans who are covered by health insurance plans, 85 percent — or 177 million Americans* — receive health coverage through an employer. This report demonstrates many different ways employers are helping to drive a health care system that delivers better health care quality and value. I hope you find this report helpful. Sincerely, Brian Moynihan Chairman and Chief Executive Officer Bank of America * Bureau of Labor Statistics, Health Insurance Coverage in the United States: 2015, Current Population Reports, September 2016.
    [Show full text]
  • The Year of Investment, Innovation and Implementation
    2017 the year of investment, innovation and implementation 2017 annual report healthcare businesswomen’s association table of contents LETTER FROM CHAIR 1 INVESTMENT 2017 BY THE NUMBERS 2 MEMBERSHIP 2 CHAPTER BREAKDOWN 2 40 YEARS OF MILESTONES 2 MEMBER/VOLUNTEER SURVEY RESULTS 3 FINANCIALS 4 INNOVATION AND IMPLEMENTATION 2017 FLAGSHIP EVENTS 7 WOMAN OF THE YEAR 8 LUMINARIES 10 RISING STARS 11 ANNUAL CONFERENCE 13 ACE AWARDS 14 THE GENDER PARITY COLLABORATIVE CLICK HERE HBA “NOW” THE NEW OPERATING MODEL CLICK HERE IN APPRECIATION—WE COULDN’T DO IT WITHOUT YOU 2017 CORPORATE PARTNERS 15 2017 SPONSORS 16 2017 MEDIA PARTNERS 17 HBA ADVISORY BOARD 18 HBA BOARD OF DIRECTORS 19 LETTER FROM CEO LAURIE COOKE 20 HBA 2017 II annual report letter from the chair In my long career as a healthcare executive, I have seen firsthand the benefits of diversity in leadership time and again. From gender to ethnicity to age and other factors, the best engagement and the most powerful results always arise when there is a diversity of perspectives in the room. This is why I joined the HBA board. This year marks the 40th anniversary of the organization’s founding. And though I am a relatively new member, I quickly became a believer in the HBA’s rich history and deep commitment to both the advancement of women individually, and to the achievement of gender parity in healthcare overall. This is also why I am proud of the HBA’s aggressive—but achievable—strategic plan to move the needle on gender parity through partnership by 2020.
    [Show full text]
  • CONCERT PHARMACEUTICALS, INC. (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material under §240.14a-12 CONCERT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required. ¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: ¨ Fee paid previously with preliminary materials. ¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: 1 Concert Pharmaceuticals, Inc.
    [Show full text]
  • ANNUAL and SUSTAINABILITY REPORT 2017 Forward-Looking Statements This Report Includes Forward-Looking State- Ments
    Building on our strengths Building ANNUAL AND SUSTAINABILITY REPORT 2017 Forward-looking statements This report includes forward-looking state- ments. Actual results may differ from those stated. Internal factors such as the successful management of research programmes and intellectual property rights may affect future results. There are also external conditions such as the economic climate, political changes and competing research programmes that may affect Sobi’s results. Sobi™ is an international biotechnology company dedicated to rare diseases. Our mission is to transform the lives of people with rare diseases by providing inno ­ vative therapies in our focus areas.” Guido Oelkers, CEO CONTENTS Contents This is Sobi .......................................................................4 The year in brief ..........................................................6 INTERVIEW Interview with the CEO and Chairman ......................8 CEO and Chairman Strategy .....................................................................10 8 Sobi operates throughout the entire value chain, from early research, over to clinical development and into the commercial market. Business areas ...............................................................16 “We can add significant value to our partnerships by leveraging all Haemophilia ..............................................................16 our com petencies, making us the partner of choice for a range of Specialty Care ...........................................................22 companies
    [Show full text]